Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.

Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM, Lacap JA, Phillips GDL.

Mol Cancer Ther. 2018 Jul;17(7):1441-1453. doi: 10.1158/1535-7163.MCT-17-0296. Epub 2018 Apr 25.

PMID:
29695635
2.

Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.

Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, Pillow TH, Sadowsky J, Cheung TK, Phung Q, Haley B, Lee BC, Akita RW, Sliwkowski MX, Polson AG.

Cancer Res. 2017 Dec 15;77(24):7027-7037. doi: 10.1158/0008-5472.CAN-17-2391. Epub 2017 Oct 18.

PMID:
29046337
3.

High cell-surface density of HER2 deforms cell membranes.

Chung I, Reichelt M, Shao L, Akita RW, Koeppen H, Rangell L, Schaefer G, Mellman I, Sliwkowski MX.

Nat Commun. 2016 Sep 7;7:12742. doi: 10.1038/ncomms12742.

4.

HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment.

Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, Lau J, Yu SF, Mizraji G, Globerson Levin A, Sliwkowski MX, Levitzki A.

Cancer Immunol Res. 2016 Aug;4(8):688-97. doi: 10.1158/2326-6066.CIR-15-0203. Epub 2016 May 30.

5.

Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.

Li C, Huang S, Armstrong EA, Francis DM, Werner LR, Sliwkowski MX, van der Kogel A, Harari PM.

Mol Cancer Ther. 2015 Sep;14(9):2049-59. doi: 10.1158/1535-7163.MCT-15-0155. Epub 2015 Jul 3.

6.

Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.

Liu SD, Chalouni C, Young JC, Junttila TT, Sliwkowski MX, Lowe JB.

Cancer Immunol Res. 2015 Feb;3(2):173-83. doi: 10.1158/2326-6066.CIR-14-0125. Epub 2014 Nov 11.

7.

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).

Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V.

Clin Cancer Res. 2015 Jan 1;21(1):123-33. doi: 10.1158/1078-0432.CCR-14-2093. Epub 2014 Nov 4.

8.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
9.

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Vu T, Sliwkowski MX, Claret FX.

Biochim Biophys Acta. 2014 Dec;1846(2):353-65. doi: 10.1016/j.bbcan.2014.07.007. Epub 2014 Jul 25. Review.

10.

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.

Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4.

11.

Antibody therapeutics in cancer.

Sliwkowski MX, Mellman I.

Science. 2013 Sep 13;341(6151):1192-8. doi: 10.1126/science.1241145. Review.

PMID:
24031011
12.

Oncogenic ERBB3 mutations in human cancers.

Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S.

Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Erratum in: Cancer Cell. 2014 Apr 14;25(4):543-4.

13.

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM.

Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20.

14.

Pari passu dimers of dimers.

Sliwkowski MX.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13140-1. doi: 10.1073/pnas.1209959109. Epub 2012 Jul 31. No abstract available.

15.

PPM1H is a p27 phosphatase implicated in trastuzumab resistance.

Lee-Hoeflich ST, Pham TQ, Dowbenko D, Munroe X, Lee J, Li L, Zhou W, Haverty PM, Pujara K, Stinson J, Chan SM, Eastham-Anderson J, Pandita A, Seshagiri S, Hoeflich KP, Turashvili G, Gelmon KA, Aparicio SA, Davis DP, Sliwkowski MX, Stern HM.

Cancer Discov. 2011 Sep;1(4):326-37. doi: 10.1158/2159-8290.CD-11-0062. Epub 2011 Jul 20.

16.

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM.

Clin Cancer Res. 2012 Jun 15;18(12):3478-86. doi: 10.1158/1078-0432.CCR-11-2294. Epub 2012 Apr 13.

17.

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR.

Nat Biotechnol. 2012 Jan 22;30(2):184-9. doi: 10.1038/nbt.2108.

PMID:
22267010
18.

Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.

Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, Crocker L, Schaefer G, Sliwkowski MX, Damico-Beyer LA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1063-9. doi: 10.1007/s00280-011-1806-6. Epub 2011 Dec 28.

PMID:
22203367
19.

Treatment of HER2-positive breast cancer: current status and future perspectives.

Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L.

Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177. Review.

PMID:
22124364
20.

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C.

Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003.

21.

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.

Clin Cancer Res. 2011 Oct 15;17(20):6437-47. doi: 10.1158/1078-0432.CCR-11-0762. Review.

22.

Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.

Burris HA 3rd, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD.

Clin Breast Cancer. 2011 Oct;11(5):275-82. doi: 10.1016/j.clbc.2011.03.018. Epub 2011 May 18. Review.

PMID:
21729661
23.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

24.

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.

Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX.

Breast Cancer Res Treat. 2011 Jul;128(2):347-56. doi: 10.1007/s10549-010-1090-x. Epub 2010 Aug 21.

PMID:
20730488
25.

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX.

Cancer Res. 2010 Jun 1;70(11):4481-9. doi: 10.1158/0008-5472.CAN-09-3704. Epub 2010 May 18.

26.

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.

Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J.

J Pharmacokinet Pharmacodyn. 2010 Jun;37(3):221-42. doi: 10.1007/s10928-010-9156-2. Epub 2010 Apr 28.

PMID:
20424896
27.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA.

J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26.

PMID:
20421541
28.

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U.

J Clin Oncol. 2010 Mar 1;28(7):1215-23. doi: 10.1200/JCO.2009.22.3354. Epub 2009 Nov 9.

PMID:
19901115
29.

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.

30.

Toward an effective targeted chemotherapy for multiple myeloma.

Polson AG, Sliwkowski MX.

Clin Cancer Res. 2009 Jun 15;15(12):3906-7. doi: 10.1158/1078-0432.CCR-09-0572. Epub 2009 Jun 9.

31.

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX.

Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020. Erratum in: Cancer Cell. 2011 Dec 13;20(6):818.

32.

Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms.

Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K.

Oncogene. 2009 Mar 12;28(10):1309-19. doi: 10.1038/onc.2008.481. Epub 2009 Jan 19.

PMID:
19151766
33.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

34.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W.

Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20.

PMID:
18641636
35.

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.

Cancer Res. 2008 Jul 15;68(14):5878-87. doi: 10.1158/0008-5472.CAN-08-0380.

36.

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.

Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX.

Cancer Res. 2006 Aug 15;66(16):8163-71.

37.

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.

Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX.

Cancer Immunol Immunother. 2006 Jun;55(6):717-27. Epub 2005 Sep 3.

PMID:
16151804
38.

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G.

J Clin Oncol. 2005 Apr 10;23(11):2534-43. Epub 2005 Feb 7.

PMID:
15699478
39.

Development of herceptin.

Carter P, Fendly BM, Lewis GD, Sliwkowski MX.

Breast Dis. 2000;11:103-11. No abstract available.

PMID:
15687596
40.

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH.

Mol Biol Cell. 2004 Dec;15(12):5268-82. Epub 2004 Sep 22.

41.

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX.

Cancer Cell. 2004 Apr;5(4):317-28.

43.

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S.

Mol Cell. 2003 Sep;12(3):541-52. Review.

44.

Preclinical studies with Erlotinib (Tarceva).

Akita RW, Sliwkowski MX.

Semin Oncol. 2003 Jun;30(3 Suppl 7):15-24. Review. Erratum in: Semin Oncol. 2003 Dec;30(6):826.

PMID:
12840797
45.

Ready to partner.

Sliwkowski MX.

Nat Struct Biol. 2003 Mar;10(3):158-9. No abstract available.

PMID:
12605220
46.

Perspectives on anti-HER monoclonal antibodies.

Ranson M, Sliwkowski MX.

Oncology. 2002;63 Suppl 1:17-24. Review.

PMID:
12422051
47.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX.

Cancer Cell. 2002 Aug;2(2):127-37.

48.

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

Stamos J, Sliwkowski MX, Eigenbrot C.

J Biol Chem. 2002 Nov 29;277(48):46265-72. Epub 2002 Aug 23.

49.

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.

Penuel E, Akita RW, Sliwkowski MX.

J Biol Chem. 2002 Aug 9;277(32):28468-73. Epub 2002 May 8.

50.

Structural requirements for ErbB2 transactivation.

Penuel E, Schaefer G, Akita RW, Sliwkowski MX.

Semin Oncol. 2001 Dec;28(6 Suppl 18):36-42. Review.

PMID:
11774204

Supplemental Content

Loading ...
Support Center